1. |
Tham I, Lu J. Controversies and challenges in the current management of nasopharyngeal cancer[J]. Expert Rev Anticancer Ther, 2010, 10(9): 1439-1450.
|
2. |
Le Tourneau C, Siu L. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck[J]. Curr Opin Oncol, 2008, 20(3): 256-263.
|
3. |
呂汪霞,馬勝林. 西妥昔單抗的臨床研究新進展[J]. 醫學綜述, 2010, 16(9): 1345-1348.
|
4. |
Pryor D, Porceddu S, Burmeister B, et al. Enhanced toxicity with concurrent cetuximab and radiotherapy in head and neck cancer[J]. Radiother Oncol, 90(2): 172-176.
|
5. |
Baselga J. The EGFR as a targe for anti-cancer therapy focus on cetuximab[J]. Eur J Cancer, 2001, 37(Suppl 4): 16-22.
|
6. |
David E. Cetuximab in metastatic colorectal cancer[J]. London Cancer New Drugs Grorp-APC/DTC Briefing, 2005, 7(1): 1-10.
|